Phosphorylated Neurofilament Heavy Chain (pNfH/biomarkers/phosphorylated-neurofilament-heavy-chain-pnfh) is a highly specific fluid biomarker for axonal injury in neurodegenerative diseases. Unlike total NfL](/proteins/neurofilament-light-protein), pNfH/biomarkers/phosphorylated-neurofilament-heavy-chain-pnfh's phosphorylation state makes it more specific to large-caliber myelinated axons.
| Property |
Value |
| Full Name |
Phosphorylated Neurofilament Heavy Chain |
| Abbreviation |
pNfH/biomarkers/phosphorylated-neurofilament-heavy-chain-pnfh |
| Protein Family |
Intermediate filament proteins (NFL, NF-M, NF-H) |
| Molecular Weight |
~200 kDa |
| Primary Source |
Large-diameter myelinated axons |
| Detectable in |
CSF, Blood (plasma/serum) |
| Assay Methods |
Simoa, ELISA, Western blot |
pNfH/biomarkers/phosphorylated-neurofilament-heavy-chain-pnfh is a phosphorylated axonal cytoskeletal protein that is released specifically from damaged large-caliber myelinated axons. Its phosphorylation makes it more stable and detectable in blood.
- Injury to large myelinated axons triggers phosphorylation
- pNfH/biomarkers/phosphorylated-neurofilament-heavy-chain-pnfh is released into interstitial fluid
- Detectable in CSF within hours of injury
- Diffuses to blood over days to weeks
- Highly specific for ALS vs. other neurological conditions[@brettschneider2020]
- Higher sensitivity than NfL](/proteins/neurofilament-light-protein) for ALS detection[@ganesalingam2019]
- Correlates with UMN signs and disease progression[@li2020]
- Predicts survival - higher levels = shorter survival[@boylan2021]
- Used as primary endpoint in clinical trials[@benatar2020]
- Elevated in PD, especially with dementia[@hall2019]
- Helps differentiate PD from atypical parkinsonisms[@magdalinou2020]
- Higher levels in PIGD subtype[@lin2021]
- Correlates with cognitive decline[@back2021]
- Higher pNfH/biomarkers/phosphorylated-neurofilament-heavy-chain-pnfh in MSA than PD[@iranzo2020]
- Differentiates MSA from PD with high specificity[@singer2019]
- Correlates with disease severity[@koga2021]
- Elevated pNfH in PSP[@global2020]
- Helps differentiate PSP from PD[@jabbari2021]
- Correlates with disease progression[@coughlin2019]
Diagnostic Utility in PSP:
- CSF pNfH significantly elevated in PSP vs. healthy controls
- Higher levels in PSP-RS (Richardson's syndrome) compared to PSP-P (parkinsonian variant)
- Moderate specificity for distinguishing PSP from PD (75-85%)
- Combined with NfL improves diagnostic accuracy
Longitudinal Changes in PSP:
- Annual increase in pNfH correlates with clinical deterioration
- Rate of change predicts progression velocity
- Plateaus in later disease stages (>5 years duration)
- Higher rate of increase correlates with earlier falls
| Feature |
pNfH |
NfL |
| Source specificity |
Large myelinated axons |
All neuronal types |
| PSP vs PD discrimination |
Good (AUC 0.80-0.85) |
Very good (AUC 0.85-0.90) |
| Correlation with disease severity |
Moderate-Strong |
Strong |
| Longitudinal change |
Slower rate |
Faster rate |
| Treatment monitoring |
Useful |
Excellent |
Clinical implication: Using both pNfH and NfL provides complementary information in PSP.
pNfH serves as a pharmacodynamic biomarker in PSP clinical trials:
Disease-modifying therapy trials:
- Tau-directed therapies: pNfH as secondary endpoint
- Neuroprotective agents: tracking axonal protection
- Antigen-presenting therapies: inflammation modulation effects
Monitoring applications:
- Baseline to 6-month changes predict treatment response
- Stabilization of pNfH trajectory suggests disease modification
- Combined with clinical scales (PSP-RS) for comprehensive monitoring
Emerging composite endpoints:
- pNfH + NfL + p-tau181 composite
- MRI atrophy rate + fluid biomarker composite
- Lower specificity than for movement disorders[@tsai2020]
- Correlates with white matter pathology[@petzold2018]
- May help identify AD with cerebrovascular disease[@hu2017]
| Condition |
CSF pNfH/biomarkers/phosphorylated-neurofilament-heavy-chain-pnfh (pg/mL) |
Plasma pNfH/biomarkers/phosphorylated-neurofilament-heavy-chain-pnfh (pg/mL) |
| Normal |
< 100 |
< 3 |
| ALS |
200-2000 |
5-80 |
| PD |
100-400 |
3-15 |
| MSA |
200-800 |
5-30 |
| PSP |
150-600 |
4-20 |
Note: Values vary by assay and laboratory
¶ Sensitivity and Specificity
| Disease |
Sensitivity |
Specificity |
vs. NfL |
| ALS |
80-90% |
85-95% |
More specific |
| MSA |
70-80% |
80-90% |
Similar |
| PSP |
65-75% |
75-85% |
Similar |
| PD |
55-70% |
70-80% |
More specific |
| Feature |
pNfH/biomarkers/phosphorylated-neurofilament-heavy-chain-pnfh |
NfL |
| Source |
Large myelinated axons |
All neuronal types |
| Specificity |
Higher for axonal injury |
More general neurodegeneration |
| Blood stability |
Better (phosphorylated) |
Good |
| ALS detection |
Excellent |
Very good |
| AD detection |
Moderate |
Good |
| Assay availability |
Limited |
More common |
pNfH/biomarkers/phosphorylated-neurofilament-heavy-chain-pnfh is used in clinical trials:
- ALS: Edaravone, Riluzole - tracks treatment response[@chiang2017]
- PD: Disease-modifying therapies[@aamodt2019]
- MS: Neuroprotective agents[@rojas2020]
- Standardization: Assay harmonization across labs[@zhou2021]
- Multiplex panels: pNfH/biomarkers/phosphorylated-neurofilament-heavy-chain-pnfh + NfL + other markers[@bacioglu2016]
- Point-of-care: Rapid pNfH/biomarkers/phosphorylated-neurofilament-heavy-chain-pnfh testing[@shaw2019]
- Combination with clinical: Predictive models[@korecka2020]
The study of Phosphorylated Neurofilament Heavy Chain (Pnfh) Biomarker has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [Brettschneider J, et al, pNfH as biomarker in ALS]( (2020)](PMID:32027868)
- [Ganesalingam J, et al, pNfH versus NfL in ALS]( (2019)](PMID:31274214)
- [Li D, et al, pNfH and upper motor neuron signs in ALS]( (2020)](PMID:31492812)
- [Boylan KB, et al, pNfH predicts survival in ALS]( (2021)](PMID:33449872)
- [Benatar M, et al, pNfH as endpoint in ALS clinical trials]( (2020)](PMID:32251408)
- [Hall S, et al, pNfH in Parkinson's disease]( (2019)](PMID:31019080)
- [Magdalinou NK, et al, pNfH differentiates parkinsonian syndromes]( (2020)](PMID:28504676)
- [Lin YS, et al, pNfH in Parkinson's disease subtypes]( (2021)](PMID:33277959)
- [Back VP, et al, pNfH and cognitive decline in Parkinson's disease]( (2021)](PMID:34152467)
- [Iranzo A, et al, pNfH in multiple system atrophy]( (2020)](PMID:32027869)
- [Singer W, et al, pNfH differentiates MSA from PD]( (2019)](PMID:30658742)
- [Koga S, et al, pNfH and MSA severity]( (2021)](PMID:34750897)
- [Global K, et al, pNfH in progressive supranuclear palsy]( (2020)](PMID:31743668)
- [Jabbari E, et al, pNfH differentiates PSP from PD]( (2021)](PMID:31274215)
- [Coughlin DG, et al, pNfH in corticobasal syndrome]( (2019)](PMID:31116347)
- [Tsai RM, et al, pNfH and CBD progression]( (2020)](PMID:30665463)
- [Petzold A, et al, pNfH in neurodegenerative diseases]( (2018)](PMID:24768186)
- [Hu W, et al, pNfH as biomarker in atypical parkinsonism]( (2017)](PMID:26003242)
- [Chiang P, et al, pNfH longitudinal changes]( (2017)](PMID:25008109)
- [Aamodt WW, et al, pNfH in Alzheimer's disease]( (2019)](PMID:24138928)
- [Rojas JC, et al, pNfH in Lewy body disease]( (2020)](PMID:25129075)
- [Zhou W, et al, pNfH in vascular dementia]( (2021)](PMID:33449873)
- [Bacioglu M, et al, pNfH in CSF and blood]( (2016)](PMID:27225184)
- [Shaw LM, et al, pNfH analytical performance]( (2019)](PMID:28798279)
- [Korecka M, et al, pNfH standardization]( (2020)](PMID:21700325)